A potent noncompetitive angiotensin II antagonist induces only competitive inhibition of angiotensin III responses.
Sarcosyl1, cysteinyl-S-methyl8-angiotensin II [(Sar1, Cys-Me8) Ang II] was examined for antagonism of angiotensin (Ang) responses in isolated rabbit atrial and aortic tissues. (Sar1, Cys-Me8) Ang II competitively antagonized Ang II responses in aorta at a concentration of 5 nM. Concentrations of the antagonist greater than 5 nM resulted in noncompetitive antagonism of Ang II responses in cardiac and vascular smooth muscle. These actions of (Sar1, Cys-Me8) Ang II were significant (p less than 0.01) and depressed maximal responses to Ang II as much as 80%. In contrast, (Sar1, Cys-Me8) Ang II at concentrations up to 10(-6) M did not significantly alter maximal responses to Ang III at any concentration in any of the experimental preparations. The antagonist did competitively inhibit Ang III concentration-dependent responses in the aorta and, to a lesser extent, in isolated atria. Saralasin was a competitive antagonist of Ang II and III in atrial and aortic preparations. Norepinephrine responses in cardiac and vascular tissues were not altered by these antagonists. The different types of antagonism exhibited by (Sar1, Cys-Me8) Ang II against Ang II and III in identical preparations demonstrate the potential for the existence of separate Ang receptors.
D000804:Angiotensin II / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D000805:Angiotensin III / Q000037:antagonists & inhibitors*; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects; D001667:Binding, Competitive / Q000187:drug effects; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009200:Myocardial Contraction / Q000187:drug effects; D011817:Rabbits; D012504:Saralasin / Q000494:pharmacology
C024549:angiotensin II, Sar(1)-S-Me-Cys(8)-; D000804:Angiotensin II; D000805:Angiotensin III; D012504:Saralasin